Develop a research agenda to address the development and validation of diagnostic strategies for molecular subtypes of epithelial ovarian carcinomas to include:
- Biomarkers that are needed for critical pathways,
- Biomarkers that are in development but need clinical grade validation, and
- Biomarkers that are CLIA approved and ready for use in clinical trials.
Develop a research agenda for phase II and III evaluation of agents that target molecularly defined pathways to include:
- Novel combinations and combinations with standard chemotherapy in epithelial ovarian carcinoma,
- Agents that show preclinical promise, agents that are in early-phase trials, and
- Agents/combinations ready for phase III trials.
Based on input from this meeting, a consensus will be reached on the most important clinical trials to conduct and a strategy for implementationthe GCSC Steering Committee will develop plans for implementation of the translational research required for the goals listed above. The intent is to prepare a list of actual trials that could be implemented over the next 3 – 5 years in 2012-2013 that could be developed.